



Nebraska Medicaid DUR Board Meeting

Tuesday January 13th, 2026

DRAFT pending approval at the next meeting

DUR Board Members in attendance: Marin Broucek, M.D., Matt Titchener R.P., Charlie Moore, R.P., David Randolph, R. P., Jaci Timmons, M.D.

Nebraska Medicaid and LTC attendees in attendance: Lee Stutzman, R.P., Pharmacy Director, Leah Spencer, RN, Program Specialist, Dianne Garside, R.P., Spencer Moore, R.P.

Contracted attendees: Jamie Benson, R.P., Maria Martin, R.P., Nebraska Total Care; Michael Labadie, R.P., Molina Healthcare

Public attendees: Kurt Hendrickson, AbbVie; John Bullard, Alexion; Shawn Akey, Concis; Miranda Ryzenman, Artia; John Freeland, Novo Nordisk; Raj Selvaraj, Novo Nordisk; Randall Roth, Merck; Nikki Asse, Jeff Houston, Ann Marie O'Toole, John Suelzer

I. Opening and Introductions

Lee Stutzman called the meeting to order at 6:30 PM. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. A copy of the Opens Meetings Act was available.

II. Declaration of any Conflict of Interest or changes

No changes in conflict of interest were noted.

III. Agenda approval

The meeting agenda was approved as follows: Broucek-yes, Titchener-yes, Timmons-yes, Moore-did not vote, Randolph- absent,

IV. Review and Approval of Minutes from previous Board meeting

The previous meeting minutes were approved as follows: Titchener-yes, Broucek-yes, Timmons-abstain, Moore-did not vote, Randolph-absent

V. Update on Recommendations from Previous Meeting

Lee Stutzman provided updates on letters sent to prescribers regarding concomitant prescribing of GLP-1s and DPP4s. The current response rate was presented to the board.

VI. Retrospective DUR

Old Business

Spencer Moore presented final data on buprenorphine utilization following the posting of the clinical guidance document in May 2025. An increase in the number of prescribers was noted.

New Business

Spencer Moore presented data on opioids, benzodiazepines, antipsychotics, and antiepileptic medications given concomitantly.

VII. Prospective DUR

Old Business:

Fee-For-Service PA annual review;

Dianne Garside presented the Immunomodulators PA form revisions. A motion to approve the form as written was made by Broucek and approved as follows: Broucek-yes, Moore-yes, Randolph-absent, Timmons-yes, Titchener-yes,

New Business

Dianne Garside presented the Wegovy PA form. New indication criteria for MASH was added to the existing Wegovy PA form. A motion to approve the form with revisions to differentiate the correct dosage forms with their indications was made by Titchener and approved as follows: Broucek-yes, Moore-yes, Randolph-yes, Timmons-yes, Titchener-yes.

VIII. Special Requests from the Department –

Stutzman requested the Board to bring forward any ideas for potential projects for future meetings. Randolph requested the State to research concomitant use of two or more alpha-blockers to determine if a project should be brought forth in the future on this topic and specified overlap of thirty days would be an appropriate parameter if the State were to look at utilization.

IX. Future Meeting Dates

May 12th, August 18th, and October 27th, 2026 January 12th, 2027

X. Concerns and Comments from the DUR Board

None.

XI. Concerns and Comments from the DUR Director

None.

XII. Concerns and Comments from the State DHHS Representatives

None.

XIII. Concerns and Comments from the MCO Representatives

None.

XIV. Concerns and Comments from the Public Attendees

Novo-Nordisk representatives made comments regarding the presented Wegovy PA form.

XV. Adjournment

Motion to adjourn the meeting was approved at 7:21pm. No objections were made from the Board.

DRAFT